On a Twitter account called "BreenGrub" began posting. Its tweets suggested it belonged to Wallace Breen himself, who had a younger version of his mind uploaded into a host body, that of an Advisor. Valve confirms this week's security breach potentially exposed encrypted credit card numbers, passwords, addresses, more. doi:10.1001/ the outline here and decide for yourself. Effect of methylphenidate on apathy in patients with Alzheimer disease: The ADMET 2 randomized clinical trial. Mintzer J, Lanctôt KL, Scherer RW, et al. Please refer to the original article for a full list of disclosures. Additionally, the relatively short treatment period may further limit the findings.ĭespite the potential benefits of methylphenidate on apathy in patients with AD, the researchers wrote that “clinicians should be aware of the small to medium treatment effects sizes and the lack of effect on activities of daily living.”ĭisclosure: Multiple authors declared affiliations with the pharmaceutical industry. Given that the study population comprised mostly White patients from the US and Canadian academic centers, the researchers note that the findings may lack generalizability across other settings and patient populations. While 17 serious adverse events occurred during the 6 months, none of these events were deemed related to methylphenidate. There was no significant difference between the methylphenidate and placebo groups regarding changes in cognitive measures and QoL. Additionally, the difference in the mean change from baseline, as estimated with a longitudinal model, was 1.43 (95% CI, 1.00-2.04 P =.048). During this time, there was a significant difference between the 2 groups in the hazard ratio (HR) change (HR, 2.16 95% CI, 1.19-3.91 P =.01).Īt the 6-month follow-up, the odds ratio of experiencing an improved rating on the AD Cooperative Study Clinical Global Impression of Change for methylphenidate vs placebo was 1.90 (95% CI, 0.95-3.84 P =.07). Researchers found that the largest decrease in the NPI apathy score was reported in the first 100 days. Patients in the methylphenidate treatment arm demonstrated a significantly larger decrease over the 6-month treatment period in the NPI apathy score (mean difference, −1.25 95% CI, −2.03 to −0.47 P =.002). Additionally, the researchers also compared groups in terms of safety, cognition changes, and quality of life (QoL). Researchers assessed changes from baseline to 6 months in the Neuropsychiatric Inventory (NPI) apathy subscale or improved rating on the AD Cooperative Study Clinical Global Impression of Change. Patients were randomly assigned to either 10 mg methylphenidate twice daily (n=99) or matching placebo (n=101). The study included 200 patients (median age, 76 years) with AD, mild-to-moderate cognitive impairment, and frequent and/or severe apathy from 10 specialty clinics across North America.
0 kommentar(er)
